tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

NeOnc Technologies Holdings Inc

NTHI
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
4.910USD
+0.060+1.24%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
141.46M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์žฅ์™ธ ๊ฑฐ๋ž˜ย 16:37ย (ET)4.900USD-0.040-0.81%

NeOnc Technologies Holdings Inc ์ •๋ณด ํšŒ์‚ฌ

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

NeOnc Technologies Holdings Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ NTHI
ํšŒ์‚ฌ ์ด๋ฆ„NeOnc Technologies Holdings Inc
์ƒ์žฅ์ผMar 26, 2025
CEOHeshmatpour (Amir F)
์ง์› ์ˆ˜- -
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMar 26
์ฃผ์†Œ23975 Park Sorrento
๋„์‹œCALABASAS
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ91302
์ „ํ™”13106637831
์›น์‚ฌ์ดํŠธhttps://neonc.com/
์ข…๋ชฉ ์ฝ”๋“œ NTHI
์ƒ์žฅ์ผMar 26, 2025
CEOHeshmatpour (Amir F)

NeOnc Technologies Holdings Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Bader Almonawer
Mr. Bader Almonawer
Independent Director
Independent Director
50.16K
--
Mr. Bader Almonawer
Mr. Bader Almonawer
Independent Director
Independent Director
50.16K
--
Ms. Nasim Shomali
Ms. Nasim Shomali
Director
Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Ms. Nasim Shomali
Ms. Nasim Shomali
Director
Director
50.16K
--
Mr. Bader Almonawer
Mr. Bader Almonawer
Independent Director
Independent Director
50.16K
--
Ms. Nasim Shomali
Ms. Nasim Shomali
Director
Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer and Chief Scientific Officer, Vice Chairman, Founder
Chief Medical Officer and Chief Scientific Officer, Vice Chairman, Founder
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ali Alabedin
Mr. Ali Alabedin
Director
Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Bader Almonawer
Mr. Bader Almonawer
Independent Director
Independent Director
50.16K
--
Mr. Bader Almonawer
Mr. Bader Almonawer
Independent Director
Independent Director
50.16K
--
Ms. Nasim Shomali
Ms. Nasim Shomali
Director
Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Ms. Nasim Shomali
Ms. Nasim Shomali
Director
Director
50.16K
--
Mr. Bader Almonawer
Mr. Bader Almonawer
Independent Director
Independent Director
50.16K
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

NeOnc Technologies Holdings Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
NeOnc Technologies Holdings Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Ms. Nasim Shomali
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ